bepridil has been researched along with Torsade de Pointes in 17 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 9.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 9.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 8.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| "Although bepridil is a useful anti-arrhythmic agent for atrial fibrillation, the appearance of serious ventricular arrhythmia, such as torsades de pointes, might be a problem." | 5.14 | Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event. ( Ishikawa, S; Izumi, T; Kiryu, M; Kosukegawa, T; Kurokawa, S; Moriguchi, M; Murakami, M; Niwano, H; Niwano, S; Yumoto, Y, 2010) |
| "Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL)." | 5.12 | Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. ( Daida, H; Kawano, Y; Nakazato, K; Nakazato, Y; Sasaki, A; Tokano, T; Yasuda, M, 2006) |
| "Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF)." | 5.12 | Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. ( Fukushima Kusano, K; Hashimoto, T; Hiramatsu, S; Kaseno, K; Miyaji, K; Naito, S; Nakamura, K; Ohe, T; Oshima, S; Tada, H; Tadokoro, K; Taniguchi, K, 2007) |
| "Bepridil prolongs the QT interval and can induce torsade de pointes." | 4.02 | Relationship between serum bepridil concentration and corrected QT interval. ( Hayakawa, N; Hosomi, K; Kawabata, A; Kusano, K; Matsui, K; Mukai, Y; Nakamura, T; Sakakura, K; Takada, M; Terakawa, N; Wada, K; Yokoyama, S, 2021) |
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 4.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| "Bepridil is highly effective in the treatment of atrial fibrillation, but its clinical usefulness is limited by a potential risk for the drug-induced Torsades de pointes (TdP) in association with its Class III action." | 3.75 | Opposing effects of bepridil on ventricular repolarization in humans. Inhomogeneous prolongation of the action potential duration vs flattening of its restitution kinetics. ( Hasebe, H; Kodama, I; Kuroda, Y; Kushiyama, Y; Osaka, T; Suzuki, T; Yokoyama, E, 2009) |
| "Bepridil is a calcium antagonist with a unique electrophysiologic profile, a long elimination half-life, and demonstrated efficacy as an antianginal agent in the setting of chronic stable angina." | 2.38 | Bepridil therapy: guidelines for patient selection and monitoring of therapy. ( Singh, BN, 1992) |
| " The QT interval was prolonged after the administration of bepridil and amiodarone, and torsades de pointes arrhythmia was induced in 3 out of 4 dogs after the bepridil administration, which was not observed during the chronic administration of amiodarone." | 1.35 | Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. ( Nakamura, Y; Sugiyama, A; Takahara, A, 2008) |
| "She was diagnosed as having sick sinus syndrome and a permanent pacemaker was therefore implanted." | 1.32 | A case of sick sinus syndrome that developed torsades de pointes, pacing failure and sensing failure during administration of bepridil. ( Chiba, N; Hiramori, K; Hotta, K; Kunugita, F; Nakamura, M; Ohsawa, M; Saito, H; Shiroto, T; Tanaka, F, 2003) |
| " The 9-year French experience suggests that bepridil is a safe and effective agent for treatment of angina pectoris in properly selected patients." | 1.28 | Safety of bepridil: from review of the European data. ( Coumel, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Matsui, K | 1 |
| Mukai, Y | 1 |
| Sakakura, K | 1 |
| Wada, K | 1 |
| Nakamura, T | 1 |
| Kawabata, A | 1 |
| Terakawa, N | 1 |
| Hayakawa, N | 1 |
| Kusano, K | 1 |
| Hosomi, K | 1 |
| Yokoyama, S | 1 |
| Takada, M | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 1 |
| Sugiyama, A | 2 |
| Takahara, A | 1 |
| Nakamura, Y | 1 |
| Osaka, T | 1 |
| Yokoyama, E | 1 |
| Kushiyama, Y | 1 |
| Hasebe, H | 1 |
| Kuroda, Y | 1 |
| Suzuki, T | 1 |
| Kodama, I | 1 |
| Kurokawa, S | 1 |
| Niwano, S | 1 |
| Kiryu, M | 1 |
| Murakami, M | 1 |
| Ishikawa, S | 1 |
| Yumoto, Y | 1 |
| Moriguchi, M | 1 |
| Niwano, H | 1 |
| Kosukegawa, T | 1 |
| Izumi, T | 1 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 1 |
| Rosenbaum, DS | 1 |
| Ohsawa, M | 1 |
| Tanaka, F | 1 |
| Kunugita, F | 1 |
| Saito, H | 1 |
| Nakamura, M | 1 |
| Shiroto, T | 1 |
| Hotta, K | 1 |
| Chiba, N | 1 |
| Hiramori, K | 1 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Sasaki, A | 1 |
| Kawano, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Daida, H | 1 |
| Miyaji, K | 1 |
| Tada, H | 1 |
| Fukushima Kusano, K | 1 |
| Hashimoto, T | 1 |
| Kaseno, K | 1 |
| Hiramatsu, S | 1 |
| Tadokoro, K | 1 |
| Naito, S | 1 |
| Nakamura, K | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Ohe, T | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 1 |
| Campens, D | 1 |
| Viallon, A | 1 |
| Laporte-Simitsidis, S | 1 |
| Pouzet, V | 1 |
| Venet, C | 1 |
| Tardy, B | 1 |
| Zéni, F | 1 |
| Bertrand, JC | 1 |
| Coumel, P | 1 |
| Singh, BN | 1 |
2 reviews available for bepridil and Torsade de Pointes
| Article | Year |
|---|---|
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
Bepridil therapy: guidelines for patient selection and monitoring of therapy.
Topics: Arrhythmias, Cardiac; Bepridil; Drug Synergism; Humans; Torsades de Pointes | 1992 |
3 trials available for bepridil and Torsade de Pointes
| Article | Year |
|---|---|
Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Follow-Up | 2010 |
Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bepridil; Bradycardi | 2006 |
Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Drug Therapy, Combination; Electrocardi | 2007 |
12 other studies available for bepridil and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Relationship between serum bepridil concentration and corrected QT interval.
Topics: Bepridil; Electrocardiography; Humans; Japan; Long QT Syndrome; Retrospective Studies; Torsades de P | 2021 |
Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model.
Topics: Animals; Atrioventricular Block; Bepridil; Cisapride; Computer Simulation; Macaca fascicularis; Sota | 2021 |
Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Bepridil; Dogs; Electrocardiogr | 2008 |
Opposing effects of bepridil on ventricular repolarization in humans. Inhomogeneous prolongation of the action potential duration vs flattening of its restitution kinetics.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies | 2009 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
A case of sick sinus syndrome that developed torsades de pointes, pacing failure and sensing failure during administration of bepridil.
Topics: Aged; Anti-Arrhythmia Agents; Bepridil; Combined Modality Therapy; Electric Countershock; Electrocar | 2003 |
Torsade de pointes.
Topics: Anti-Arrhythmia Agents; Bepridil; Bradycardia; Electrocardiography; Heart Block; Humans; Hypokalemia | 1996 |
[Bepridil: importance of serum level in treatment surveillance].
Topics: Aged; Aged, 80 and over; Bepridil; Dose-Response Relationship, Drug; Drug Monitoring; Electrocardiog | 2000 |
Safety of bepridil: from review of the European data.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Bepridil; Clinical Trials as Topic; Female; France; Humans | 1992 |